In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients

Cancer Immunology, Immunotherapy

Volumn 58, Issue 1, 2009, Pages 31-38

  Santini, Daniele ^a   Martini, Federico ^b   Fratto, Maria Elisabetta ^a   Galluzzo, Sara ^a   Vincenzi, Bruno ^a   Agrati, Chiara ^b   Turchi, Federica ^b   Piacentini, Paola ^b   Rocci, Laura ^a   Manavalan, John S ^c   Tonini, Giuseppe ^a   Poccia, Fabrizio ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

T cells; Bisphosphonates; Cancer patients; Zoledronic acid

Indexed keywords

CD27 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; OSTEOPENIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LYMPHOCYTE SUBSETS; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 54849441655     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0521-6     Document Type: Article

References (32)

1. JR Green K Muller KA Jaeggi 1994 Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound J Bone Miner Res 9 745 751
2. WK Sietsema FH Ebetino AM Salvagno JA Bevan 1989 Antiresorptive dose-response relationship across three generations of bisphosphonates Drugs Exp Clin Res 15 389 396
3. BE Hillner JN Ingle RT Chlebowski J Gralow GC Yee NA Janjan JA Cauley 2004 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 22 1351
4. F Saad D Gleason R Murray 2003 Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone J Urol 169 suppl 394
5. LS Rosen D Gordon NS Tchekmedyian R Yanagihara V Hirsh M Krzakowski M Pawlicki 2004 Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2613 2621
6. E Van Beek E Pieterman L Cohen C Lowick S Papapoulous 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem Biophys Res Commun 264 108 111
7. FL Zhang PJ Casey 1996 Protein prenylation: molecular mechanisms and functional consequences Annu Rev Biochem 65 241 269
8. D Santini U Vespasiani Gentilucci B Vincenzi A Picardi F Vasaturo A LaCesa N Onori 2003 The antineoplastic role of bisphosphonates: from basic research to clinical evidence Ann Oncol 14 1468 1476
9. D Kabelitz L Marischen HH Oberg W Holtmeier D Wesch 2005 Epithelial defence by γ/δ T cells Int Arch Allergy Immunol 137 73 81
10. T Hiraga PJ Williams A Ueda D Tamura D Yoneda 2004 Zoledronic acid inhibits visceral metastasis in the 4T1/luc mouse breast cancer model Clin Cancer Res 10 4554 4567
11. N Caccamo S Meraviglia V Ferlazzo D Angelini G Borsellino F Poccia L Battistini 2005 Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naïve, memory and effector T cell subsets Eur J Immunol 35 1764 1772
12. MR Zocchi M Ferrarini C Rugarli 1990 Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas Eur J Immunol 20 2685 2689
13. A Choudhary F Davodeau A Moreau MA Peyrat M Bonneville F Jotereau 1995 Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma J Immunol 154 3932 3940
14. X Zhao YQ Wei Y Kariya K Teshigawara A Uchida 1995 Accumulation of gamma/delta T cells in human dysgerminoma and seminoma: roles in autologous tumor killing and granuloma formation Immunol Invest 24 607 618
15. M Bagot M Heslan L Dubertret JC Roujeau R Tourine JP Levy 1985 Antigen-presenting properties of human epidermal cells compared with peripheral blood mononuclear cells Br J Dermatol 113 suppl 28 55
16. AD Laad ML Thomas AR Fakih SV Chiplunkar 1990 Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells Int J Cancer 80 709 714
17. P Fisch M Malkovsky S Kovats E Sturm E Braakman BS Klein SD Voss 1990 Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells Science 250 1269 1273
18. MS Freedman S D'Souza JP Antel 1997 Gamma delta T-cell-human glial cell interactions In vitro induction of gamma-delta T-cell expansion by human glial cells J Neuroimmunol 74 135 142
19. Y Suzuki Y Fujimiya T Ohno R Katakura T Yoshimoto 1999 Enhancing effect of tumor necrosis factor (TNF)-alpha, but not IFN-gamma, on the tumor-specific cytotoxicity of gammadelta T cells from glioblastoma patients Cancer Lett 140 161 167
20. KE Schilbach A Geiselhart JT Wessels D Niethammer R Handgretinger 2000 Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells J Immunother 23 536 548
21. M Courvasier A Moureau-Aubry E Diez J Bennouna JF Mosnier E Scotet M Bonneville 2005 Vγ9/Vδ2 T cell response to colon carcinoma cells J Immunol 175 8 5481 5488
22. M Ferrarini E Ferrero L Dagna A Poggi MR Zocchi 2002 Human gammadelta T cells: a nonredundant system in the immune surveillance against cancer Trends Immunol 23 14 18
23. V Kunzmann E Bauer J Feurle F Weissinger HP Tony M Wilhelm 2000 Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasmacell activity in multiple myeloma Blood 96 384 392
24. V Kunzmann E Bauer M Wilhelm 1999 γδ T cell stimulation by pamidronate N Engl J Med 340 737 738
25. F Dieli N Gebbia F Poccia N Caccamo C Montesano F Fulfaro C Arcara 2003 Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo Blood 102 2310 1
26. V Ferlazzo C Sferrazza N Caccamo G Di Fede G Di Lorenzo M D'Asaro S Meraviglia 2006 In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation Int J Immunopathol Pharmacol 19 309 317
27. F Dieli F Poccia M Lipp G Sireci N Caccamo C Di Sano A Salerno 2003 Differentiation of effector/Memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites J Exp Med 198 391 397
28. S Galluzzo D Santini B Vincenzi N Caccamo F Meraviglia A Salerno F Dieli 2007 Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity Expert Opin Ther Targets 11 7 941 954
29. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 168
30. N Watanabe M Narita A Yokoyama A Sekiguchi A Saito N Tochiki T Furukawa 2006 Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate Cytotherapy 8 118 129
31. K Thompson MJ Rogers 2004 Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro J Bone Miner Res 19 2 278 288
32. MJ Rogers 2003 New insights into the molecular mechanisms of action of bisphosphonates Curr Pharm Des 9 32 2643 2658